Amaia Lujambio

11.9k total citations · 6 hit papers
54 papers, 6.1k citations indexed

About

Amaia Lujambio is a scholar working on Molecular Biology, Cancer Research and Immunology. According to data from OpenAlex, Amaia Lujambio has authored 54 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 20 papers in Cancer Research and 18 papers in Immunology. Recurrent topics in Amaia Lujambio's work include Immunotherapy and Immune Responses (10 papers), Hepatocellular Carcinoma Treatment and Prognosis (9 papers) and Epigenetics and DNA Methylation (9 papers). Amaia Lujambio is often cited by papers focused on Immunotherapy and Immune Responses (10 papers), Hepatocellular Carcinoma Treatment and Prognosis (9 papers) and Epigenetics and DNA Methylation (9 papers). Amaia Lujambio collaborates with scholars based in United States, Spain and United Kingdom. Amaia Lujambio's co-authors include Scott W. Lowe, Manel Esteller, Romain Donné, Montse Sánchez‐Céspedes, Santiago Ropero, Simona Rossi, George A. Calin, Marina Ruiz de Galarreta, David Blanco and Luis M. Montuenga and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Amaia Lujambio

54 papers receiving 6.0k citations

Hit Papers

The microcosmos of cancer 2007 2026 2013 2019 2012 2008 2007 2013 2022 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The microcosmos of cancer
    2012 917 citations Amaia Lujambio, Scott W. Lowe profile →
  2. A microRNA DNA methylation signature for human cancer metastasis
    2008 843 citations Amaia Lujambio, George A. Calin et al. profile →
  3. Genetic Unmasking of an Epigenetically Silenced microRNA in Human Cancer Cells
    2007 729 citations Amaia Lujambio, Santiago Ropero et al. Cancer Research profile →
  4. Non-Cell-Autonomous Tumor Suppression by p53
    2013 615 citations Amaia Lujambio, Vishal Thapar et al. profile →
  5. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
    2022 368 citations Romain Donné, Amaia Lujambio Hepatology profile →
  6. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
    2022 342 citations Marina Ruiz de Galarreta, Amaia Lujambio et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amaia Lujambio United States 27 4.2k 2.8k 1.2k 764 631 54 6.1k
Wei‐Zhong Wu China 41 3.5k 0.8× 1.9k 0.7× 2.1k 1.7× 1.0k 1.4× 470 0.7× 107 5.7k
Jing‐Ping Yun China 41 3.5k 0.8× 2.5k 0.9× 1.6k 1.3× 645 0.8× 863 1.4× 151 5.8k
Pnina Brodt Canada 46 3.2k 0.8× 2.2k 0.8× 2.5k 2.1× 1.1k 1.5× 689 1.1× 115 6.8k
Alana L. Welm United States 41 4.0k 0.9× 1.8k 0.7× 2.4k 1.9× 799 1.0× 745 1.2× 97 6.5k
Limin Xia China 39 2.8k 0.7× 1.4k 0.5× 1.0k 0.8× 594 0.8× 512 0.8× 142 4.1k
Junfang Ji China 25 3.1k 0.7× 2.4k 0.8× 1.3k 1.0× 348 0.5× 318 0.5× 55 4.9k
Ai‐Wu Ke China 41 3.7k 0.9× 2.2k 0.8× 1.4k 1.1× 950 1.2× 624 1.0× 93 5.9k
Zhi Dai China 38 2.7k 0.6× 1.9k 0.7× 1.7k 1.3× 1.3k 1.7× 605 1.0× 97 5.4k
Hu‐Liang Jia China 43 4.6k 1.1× 3.6k 1.3× 2.0k 1.6× 892 1.2× 661 1.0× 92 7.5k
ST Cheung Hong Kong 38 2.7k 0.6× 1.2k 0.4× 1.6k 1.3× 443 0.6× 397 0.6× 86 4.9k

Countries citing papers authored by Amaia Lujambio

Since Specialization
Citations

This map shows the geographic impact of Amaia Lujambio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amaia Lujambio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amaia Lujambio more than expected).

Fields of papers citing papers by Amaia Lujambio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amaia Lujambio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amaia Lujambio. The network helps show where Amaia Lujambio may publish in the future.

Co-authorship network of co-authors of Amaia Lujambio

This figure shows the co-authorship network connecting the top 25 collaborators of Amaia Lujambio. A scholar is included among the top collaborators of Amaia Lujambio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amaia Lujambio. Amaia Lujambio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Humblin, Étienne, Nataliya Prokhnevska, Abishek Vaidya, et al.. (2025). The costimulatory molecule ICOS limits memory-like properties and function of exhausted PD-1+CD8+ T cells. Immunity. 58(8). 1966–1983.e10. 4 indexed citations
2.
Bertrán, Esther, Javier Vaquero, Marina Ruiz de Galarreta, et al.. (2025). New Experimental Mouse Models to Evaluate the Role of Transforming Growth Factor‐Beta in Liver Tumorigenesis. Liver International. 45(10). e70351–e70351. 1 indexed citations
3.
Chen, Zhihong, Gonzalo Piñero, Bruno Giotti, et al.. (2023). Monocyte depletion enhances neutrophil influx and proneural to mesenchymal transition in glioblastoma. Nature Communications. 14(1). 1839–1839. 32 indexed citations
4.
Donné, Romain & Amaia Lujambio. (2022). The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology. 77(5). 1773–1796. 368 indexed citations breakdown →
5.
Chen, Zhihong, Gonzalo Piñero, Bruno Giotti, et al.. (2022). IMMU-23. ELIMINATING MONOCYTE CHEMOATTRACTION INVOKES COMPENSATORY NEUTROPHIL INFLUX AND PRONEURAL TO MESENCHYMAL TRANSITION IN GLIOBLASTOMA. Neuro-Oncology. 24(Supplement_7). vii136–vii136. 1 indexed citations
6.
Lujambio, Amaia, et al.. (2022). Proteomic Analyses Identify Therapeutic Targets in Hepatocellular Carcinoma. Frontiers in Oncology. 12. 814120–814120. 5 indexed citations
7.
Pal, Debjani, Trine Lindsted, Ingrid Ibarra, et al.. (2021). An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression. eLife. 10. 9 indexed citations
8.
Craig, Amanda J., Teresa García‐Lezana, Marina Ruiz de Galarreta, et al.. (2021). Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. PLoS Genetics. 17(6). e1009589–e1009589. 16 indexed citations
9.
Bárcena‐Varela, Marina & Amaia Lujambio. (2021). The Endless Sources of Hepatocellular Carcinoma Heterogeneity. Cancers. 13(11). 2621–2621. 27 indexed citations
10.
Desdouets, Chantal & Amaia Lujambio. (2021). Decoding therapy resistance in liver tumours: a giant leap. Nature Reviews Gastroenterology & Hepatology. 19(2). 83–84. 1 indexed citations
11.
Qing, Tao, Tomi Jun, Katherine E. Lindblad, et al.. (2021). Diverse immune response of DNA damage repair-deficient tumors. Cell Reports Medicine. 2(5). 100276–100276. 14 indexed citations
12.
Lindblad, Katherine E., Marina Ruiz de Galarreta, & Amaia Lujambio. (2021). Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers. Frontiers in Immunology. 12. 642958–642958. 19 indexed citations
13.
Yu, Jia Xin, Amanda J. Craig, Mary E. Duffy, et al.. (2019). Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology. Molecular Cancer Therapeutics. 18(9). 1506–1519. 17 indexed citations
14.
Valerio, Daria G., Haiming Xu, Chun‐Wei Chen, et al.. (2017). Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis. Cancer Research. 77(7). 1753–1762. 35 indexed citations
15.
Bollard, Julien, Verónica Miguela, Marina Ruiz de Galarreta, et al.. (2016). Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 66(7). 1286–1296. 206 indexed citations
16.
Martinez-Quetglas, Iris, Roser Pinyol, Daniel Dauch, et al.. (2016). IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. Gastroenterology. 151(6). 1192–1205. 100 indexed citations
17.
Appelmann, Iris, Claudio Scuoppo, Vishal Thapar, et al.. (2014). Suppression of EZH2 Accelerates MYC-Driven Lymphomagenesis By Inhibition of Apoptosis. Blood. 124(21). 3009–3009. 1 indexed citations
18.
Iliou, Maria S., Amaia Lujambio, Anna Portela, et al.. (2011). Bivalent histone modifications in stem cells poise miRNA loci for CpG island hypermethylation in human cancer. Epigenetics. 6(11). 1344–1353. 13 indexed citations
19.
Lujambio, Amaia, Anna Portela, Julia Liz, et al.. (2010). CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene. 29(48). 6390–6401. 147 indexed citations
20.
Lujambio, Amaia, Santiago Ropero, Esteban Ballestar, et al.. (2007). Genetic Unmasking of an Epigenetically Silenced microRNA in Human Cancer Cells. Cancer Research. 67(4). 1424–1429. 729 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wei‐Zhong Wu Breakdown of academic impact, for papers by Jing‐Ping Yun Breakdown of academic impact, for papers by Pnina Brodt Breakdown of academic impact, for papers by Alana L. Welm Breakdown of academic impact, for papers by Limin Xia Breakdown of academic impact, for papers by Junfang Ji Breakdown of academic impact, for papers by Ai‐Wu Ke Breakdown of academic impact, for papers by Zhi Dai Breakdown of academic impact, for papers by Hu‐Liang Jia Breakdown of academic impact, for papers by ST Cheung
Rankless by CCL
2026